Jul 2018 – Mar 2019 · 8 mos

• USD 4 billion merger with Ranbaxy
• Integration Management Office (IMO): Sun-Ranbaxy integration
• Acquisition of Ocular Technologies with lead clinical stage product, Seciera for dry eye indication
• Acquisition of Insite Vision ($48mn equity value) in branded opthalmology space in US
• Acquisition of Biosyntez, a Russian pharmaceutical company
• $230 mn acquisition of Dusa Pharmaceuticals in branded dermatology space in US
• Acquisition of URL Pharma, a US generics company
• JV with Intrexon

Apr 2016 – Jun 2018 · 2 yrs 2 mos

Apr 2015 – Mar 2016 · 11 mos

Apr 2012 – Mar 2015 · 2 yrs 11 mos

Jan 2010 – Apr 2012 · 2 yrs 3 mos · Gurgaon

• Reported to the Chairman (ex-CEO and MD, Ranbaxy)
• I worked in corporate strategy role which included the following:
• 1. End to end handling of strategic investments/ M&A transactions in pharma/healthcare domain under the guidance of company CFO
• Preliminary analysis of the target
• Preparing investment memo for the Board
• Term sheet Negotiations
• Coordinating due diligence, analyzing due diligence report and working out resolution of issues
• Reviewing the shareholders agreement
• 2. Evaluation of new investment proposals in pharmaceutical domain
• 3. Monitoring/Analyzing the performance of each of the five GVK BIO SBUs and Inogent, a GVK BIO group company
• 4. Preparation of strategy (Business and Financial) plan for each of the business units in consultation with respective business heads
• 5. Preparation of strategy plan for Inogent which is engaged in Custom Chemical Synthesis, Process R&D and API & Intermediates manufacturing
• GVK Biosciences (GVK BIO) is Asia’s leading research services organization, offering a broad spectrum of stand-alone and integrated services across the R&D value chain
• Inogent Laboratories is a fast growing company engaged in Custom Chemical Synthesis, Process R&D and API & Intermediates manufacturing

Apr 2007 – Jan 2010 · 2 yrs 9 mos

• I worked on M&A transactions in pharmaceutical domain, which primarily involved identification and analysis of opportunities/strategic alternatives for clients in US biotech/pharma space and valuation of companies using multiple valuation methodologies
• Worked on the following announced transactions:
• 1. Sell-side advisory to a US large pharma company in multi-billion dollar merger transaction
• 2. Sell-side advisory to a US biotech co. in multi-billion dollar sale of the company
• 3. Spin-off transaction of a US biotech co.

Jan 2003 – Jan 2005 · 2 yrs